Nov 23 (Reuters) - Cyclopharm Ltd (CYC)
- Received special protocol assessment (spa ) agreement1 from United States Food And Drug Administration
- Received special protocol assessment agreement1 for patient trials of its technegas product, to be known as cyc009
- Approval process remains on track for completion by mid2018 at a cost of less than $7 million usd
News: CYC Cyclopharm Ltd receives special protocol assessment agreement1 from FDA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
88.5¢ |
Change
0.115(14.9%) |
Mkt cap ! $98.35M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 89.0¢ | 78.0¢ | $101.8K | 127.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1190 | 84.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 5750 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| CYC (ASX) Chart |